- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech High Growth Potential Companies
Hong Kong Pharmaceuticals & Biotech High Growth Potential Companies
UPDATED Mar 29, 2023
Companies with a Future performance score of at least 3, ordered by Future performance score.
23 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1061Essex Bio-Technology | HK$3.82 | 3.2% | -12.0% | HK$2.2b | HK$6.00 | PE9.7x | E33.0% | 1.7% | ||
| 2096Simcere Pharmaceutical Group | HK$8.19 | -6.6% | -22.6% | HK$21.8b | HK$14.66 | PE18.9x | E52.2% | 2.1% | ||
| 2552Hua Medicine (Shanghai) | HK$3.52 | 5.7% | -8.8% | HK$3.4b | HK$5.95 | PS169.5x | E82.5% | n/a | ||
| 2315Biocytogen Pharmaceuticals (Beijing) | HK$25.00 | -0.8% | n/a | HK$10.0b | HK$33.70 | PS16.4x | E84.7% | n/a | ||
| 6622Zhaoke Ophthalmology | HK$3.83 | 0.3% | 9.4% | HK$2.1b | HK$8.32 | PB0.8x | E59.8% | n/a | ||
| 1558YiChang HEC ChangJiang Pharmaceutical | HK$7.04 | -11.7% | 45.5% | HK$6.2b | HK$10.77 | PE70.9x | E77.3% | 0% | ||
| 1801Innovent Biologics | HK$35.05 | -10.1% | 30.1% | HK$53.8b | HK$52.48 | PS10.3x | E52.7% | n/a | ||
| 1521Frontage Holdings | HK$2.38 | 3.5% | -17.6% | HK$4.8b | HK$3.41 | PE24x | E28.8% | n/a | ||
| 9939Kintor Pharmaceutical | HK$7.05 | -12.9% | -27.7% | HK$3.2b | HK$27.50 | PS80.8x | E94.9% | n/a | ||
| 2696Shanghai Henlius Biotech | HK$11.40 | -3.4% | -45.2% | HK$6.2b | HK$41.91 | PS2.3x | E97.1% | n/a | ||
| 9995RemeGen | HK$44.30 | -7.5% | -4.7% | HK$34.1b | HK$72.46 | PS26.4x | E61.5% | n/a | ||
| 1672Ascletis Pharma | HK$2.60 | -5.8% | -50.0% | HK$2.8b | HK$3.03 | PS45.8x | E85.9% | n/a | ||
| 9926Akeso | HK$41.40 | -1.8% | 148.2% | HK$34.8b | HK$56.37 | PS36.4x | E28.9% | n/a | ||
| 2005SSY Group | HK$4.62 | 14.9% | 30.5% | HK$13.7b | HK$5.44 | PE12.2x | E19.6% | 3.0% | ||
| 6185CanSino Biologics | HK$42.45 | -11.5% | -66.3% | HK$20.5b | HK$122.20 | PS8.9x | E92.1% | 2.1% | ||
| 570China Traditional Chinese Medicine Holdings | HK$4.10 | -2.4% | 0% | HK$20.6b | HK$4.50 | PE23.7x | E25.2% | 1.3% | ||
| 1877Shanghai Junshi Biosciences | HK$28.00 | -1.6% | -49.7% | HK$48.2b | HK$51.02 | PS16.6x | E76.4% | n/a | ||
| 2269WuXi Biologics (Cayman) | HK$49.30 | -2.8% | -24.2% | HK$208.5b | HK$90.72 | PE41.3x | E19.2% | n/a | ||
| 6826Shanghai Haohai Biological Technology | HK$41.20 | 4.3% | 4.0% | HK$17.0b | HK$63.43 | PE34.3x | E33.1% | 1.9% | ||
| 1681Consun Pharmaceutical Group | HK$4.65 | 6.7% | 21.7% | HK$3.7b | HK$5.79 | PE4.7x | E10.9% | 6.4% | ||
| 2186Luye Pharma Group | HK$3.65 | 7.7% | 21.7% | HK$13.7b | HK$3.25 | PE19.9x | E17.9% | n/a | ||
| 6600SciClone Pharmaceuticals (Holdings) | HK$10.40 | -1.9% | 27.9% | HK$6.3b | HK$11.84 | PE6.6x | E4.6% | 3.1% | ||
| 6660AIM Vaccine | HK$42.65 | 6.8% | n/a | HK$51.7b | HK$31.94 | PS35.8x | S61.0% | n/a |
Page 1 of 1